Biphasic Scatchard plots of oestrogen receptors are associated with low pS2 levels in human breast cancers

Cancer Letters

Volumn 144, Issue 1, 1999, Pages 17-23

  Marsigliante, S ^a   Biscozzo, L ^a   Leo, G ^b   Storelli, C ^a  

^a UNIVERSITY OF SALENTO   (Italy)

^b VITO FAZZI HOSPITAL   (Italy)

Author keywords

Breast cancer; ER; pS2; Scatchard analysis

Indexed keywords

ESTROGEN RECEPTOR; PROGESTERONE RECEPTOR; PROTEIN PS2;

ARTICLE; BREAST CANCER; CONTROLLED STUDY; ENZYME IMMUNOASSAY; FEMALE; HORMONAL THERAPY; HUMAN; HUMAN CELL; HUMAN TISSUE; PRIORITY JOURNAL; SCATCHARD PLOT;

ADULT; AGED; AGED, 80 AND OVER; BREAST NEOPLASMS; FEMALE; HUMANS; MIDDLE AGED; PROTEINS; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; TUMOR SUPPRESSOR PROTEINS;

EID: 0032783409     PISSN: 03043835     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0304-3835(99)00178-0     Document Type: Article

References (36)

1. Allegra J.C., Lippman M.E., Thompson E.B., Simon R., Bablock A., Green L., Hoff K.K., Do H.M.T., Iatken S.C., Warren R. Oestrogen receptor status: an important variable in predicting response to endocrine therapy in metastatic breast cancer. Eur. J. Cancer. 16:1980;323-331.
2. Byar D.P., Sears M.E., McGuire W.L. Relationship between oestrogen receptor values and clinical data in predicting the response to endocrine therapy for patients with advanced breast cancer. Eur. J. Cancer. 15:1979;299-310.
3. Hubay C.A., Arafah B., Gordon N.H., Guyton S.P., Crowe J.P. Hormone receptors: an update and application. Surg. Clin. N. Am. 64:1984;1155-1172.
4. Wittliff J.L. Steroid-hormone receptors in breast cancer. Cancer. 53:1984;630-643.
5. Toft D.D., Gorski J. A receptor molecule for estrogens: isolation from the rat uterus and preliminary characterisation. Proc. Natl. Acad. Sci. USA. 55:1966;1574-1581.
6. Korenman S.G., Dukes B.A. Specific estrogen binding by the cytoplasm of human breast carcinoma. J. Clin. Endocrinol. Metab. 30:1970;639-645.
7. Kirdani R.Y., Pontes E.J., Murphy G.P., Sandberg A.A. A micromethod for the measurement of estrogen receptors using high pressure liquid chromatography. J. Steroid Biochem. 17:1982;311-317.
8. Lloyd E.J., Barnes D.H., Skinner L.G. Isoelectric focussing of an estradiol-receptor protein from human mammary carcinoma: a comparison with dextran-coated charcoal assay. J. Steroid Biochem. 16:1982;239-244.
9. Poulsen H.S. Estrogen receptors in human breast cancer: Comparative features of the hydroxylapatite and dextran-coated charcoal assay. Eur. J. Cancer Clin. Oncol. 18:1982;1075-1079.
10. Leo G., Cappiello G., Poltronieri P., Giardina C., Manca C., Storelli C., Marsigliante S. Tamoxifen binding sites heterogeneity in breast cancer: a comparative studies with steroid hormone receptors. Eur. J. Cancer. 27:1991;452-455.
11. Scatchard S.S. The attractions of proteins for small molecules and ions. Ann. N.Y. Acad. Sci. 51:1949;660-672.
12. Marsigliante S., Puddefoot J.R., Barker S., Gledhill J., Vinson G.P. Discrepancies between antibody (EIA) and saturation analysis of oestrogen receptor content in breast tumour samples. J. Steroid Biochem. 37:1990;643-648.
13. King V.J., Desanbre E.R., Jensen E.V., Greene S.L. Comparison of immunocytochemical and steroid-binding assays for estrogen receptor in human breast cancer. Cancer Res. 45:1985;293-304.
14. Alexieva-Figusch J., van Putten W.L.J., Blankestein M.A., van der Wijst J.B., Klijn J.G.M. The prognostic value and relationships of patient characteristics, estrogen and progestin receptors, and site of relapse in primary breast cancer. Cancer. 61:1988;758-768.
15. Clark G.M., McGuire W.L., Hubay C.A., Pearson O.H., Marshall J.S. Progesterone receptors as a prognostic factor in stage II breast cancer. N. Engl. J. Med. 309:1983;1343-1347.
16. Rio M.C., Bellocq J.P., Daniel J.Y., Tomasetto C., Lathe R., Chenard M.P., Batzenschalager A., Chambon P. Breast cancer-associated pS2 protein: synthesis and secretion by normal stomach mucosa. Science. 24:1988;705-708.
17. Henry J.A., Piggott N.H., Mallick U.K., Nicholson S., Farndon J.R., Westley B.R., May F.E.B. pNR-2/pS2 Immunohistochemical staining in breast cancer: correlation with prognostic factors and endocrine response. Br. J. Cancer. 63:1991;615-622.
18. Predine J., Spyratos F., Prud'homme F., Andrieu C., Hacene K., Brunet M., Pallud C., Milgrom E. Enzyme-linked immunosorbent assay of pS2 in breast cancers, benign tumors, and normal breast tissues. Cancer. 69:1992;2116-2123.
19. Marsigliante S., Biscozzo L., Correale M., Paradiso A., Leo G., Abbate I., Dragone C.D., Storelli C. Immunoradiometric detection of pS2 and total cathepsin D in primary breast cancer biopsies: their correlation with steroid receptors. Br. J. Cancer. 69:1994;550-554.
20. Rio M.C., Lepage P., Diemunsch P., Roitch C., Chambon P. Structure primarie de la proéine humaine pS2. C. R. Acad. Sci. Paris. 307:1988;825-831.
21. Marsigliante S., Greco S., Biscozzo L., Barker S., Baker V., Leo G., Vinson G.P., Storelli C. Transcriptionally active non-ligand binding oestrogen receptors in breast cancer. Cancer Lett. 66:1992;183-191.
22. Rosenthal H.A. A graphic method for the determination and presentation of binding parameters in a complex system. Anal. Biochem. 20:1967;525-532.
23. Zierler K. Misuse of nonlinear Scatchard plots. Trends Biol. Sci. 14:1989;314-317.
24. r 52 000 glycoprotein: characterization and immunodetection in MCF-7 cells. Cancer Res. 45:1985;709-716.
25. Goussard J., Lechevrel C., Roussel G., Cren H., Bera O., Sala M. Immunoradiometric assay of pS2 protein in breast cancer cytosols. Clin. Chem. 37:1991;1759-1762.
26. Spyratos F., Broillet J.P., Defrenne A., Hacene K., Rouesse J., Maudelonde T., Brunet M., Andrieu C., Desplaces A., Rochefort H. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet. 8672:1989;1115-1118.
27. Brouillet J.P., Theillet C., Maudelonde T., Defrenne A., Simony-Lafontaine J., Sertour J., Pujol H., Jeanteur P., Rochefort H. Cathepsin D assay in primary breast cancer and lymph nodes: relationship with c-myc, c-erb-B-2 and int-2 oncogene amplification and node invasiveness. Eur. J. Cancer. 26:1990;437-441.
28. Marsigliante S., Biscozzo L., Greco S., Leo G., Storelli C. Relation of the cathepsin D level to the oestrogen receptor in human breast cancer. Int. J. Clin. Lab. Res. 22:1992;52-57.
29. Bradford M.M. A rapid and sensitive method for the quantitation of microgram quantities of protein utilising the principle of protein-dye binding. Anal. Biochem. 72:1976;248-254.
30. Fisher B., Wicherham D.L., Brown A., Redmond C.K. Breast cancer estrogen and progesterone receptor values: their distribution, degree of concordance, and relation to number of positive axillary nodes. J. Clin. Oncol. 1:1983;349-358.
31. Alanko A., Heinonhen E., Scheinin T., Tolppannen E.S., Vihko R. Significance of estrogen and progesterone receptors, disease-free interval, and site of first metastasis on survival of breast cancer patients. Cancer. 56:1985;1696-1700.
32. Foekens J.A., Rio M.C., Seguin P., van Putten W.L.J., Fauque J., Nap M., Klijn G.M., Chambon P. Prediction of relapse and survival in breast cancer patients by pS2 protein status. Cancer Res. 50:1990;3832-3837.
33. Cappelletti V., Coradini D., Scanziani E., Benini E., Silvestrini R., Di Fronzo G. Prognostic relevance of pS2 status in association with steroid receptor status and proliferative activity in node-negative breast cancer. Eur. J. Cancer. 28A:1992;1315-1318.
34. Schwartz L.H., Koerner F.C., Edgerton S.M., Sawicka J.M., Rio M., Bellocq J., Chanbon P., Thor A.D. pS2 expression and response to hormonal therapy in patients with advanced breast cancer. Cancer Res. 51:1991;624-628.
35. Marsigliante S., Biscozzo L., Barker S., Leo G., Puddefoot J.R., Vinson G.P., Storelli C. Type II oestrogen binding site is associated with the major 4S oestrogen receptor isoform in breast tumour. J. Steroid Biochem. 7:1992;777-781.
36. Weichman B.N., Notides A.C. Estradiol-binding kinetics of the activated and nonactivated estrogen receptor. J. Biol. Chem. 252:1977;8856-8862.